Aclaris Therapeutics, Inc.

ACRS

US00461U1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.2 ^USD	+0.84%		-3.23%	+14.29%

Mar. 19	Aclaris Therapeutics, Inc. Announces Board Resignations	CI
Feb. 27	Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023

February 27, 2024 at 07:15 am EST

Aclaris Therapeutics, Inc. announced Intangible asset impairment for the three months ended December 31, 2023. For the quarter, the company reported Intangible asset impairment of $6,629,000.

Latest news about Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. Announces Board Resignations	Mar. 19	CI
Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023	Feb. 27	CI
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q4 Revenue $17.6M	Feb. 27	MT
Aclaris Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
Aclaris Therapeutics, Inc. Announces Termination of Employment of Gail Cawkwell as Chief Medical Officer	Feb. 05	CI
North American Morning Briefing : Stock Futures -2-	Jan. 23	DJ
HC Wainwright Downgrades Aclaris Therapeutics to Neutral From Buy	Jan. 22	MT
Sector Update: Health Care Stocks Weaker Late Afternoon	Jan. 16	MT
Sector Update: Health Care Stocks Softer Tuesday Afternoon	Jan. 16	MT
Aclaris Therapeutics Shares Rise; Strategic Review Announced, CEO Manion to Step Down	Jan. 16	MT
Aclaris Therapeutics Conducts Strategic Review of Business	Jan. 16	CI
Aclaris Therapeutics, Inc. Announces Executive Changes	Jan. 16	CI
Aclaris Therapeutics, Inc. Announces Chief Executive Officer Changes	Jan. 16	CI
North American Morning Briefing : Stock Futures -2-	Jan. 12	DJ
BTIG Downgrades Aclaris Therapeutics to Neutral From Buy	Jan. 11	MT
Top Midday Decliners	Jan. 10	MT
Aclaris Therapeutics, Inc. Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis	Jan. 10	CI
Aclaris Therapeutics to Trim Workforce by 46%; Shares Fall After Hours	Dec. 19	MT
Stifel Trims Price Target on Aclaris Therapeutics to $1 From $2, Maintains Hold Rating	Dec. 18	MT
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from S&P Pharmaceuticals Select Industry Index	Dec. 18	CI
Sun Pharmaceutical Signs Licensing Pact with Aclaris Therapeutics	Dec. 05	MT
Indian shares set to open at new record highs for third session	Dec. 05	RE
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia	Dec. 05	CI

Chart Aclaris Therapeutics, Inc.

Duration

Period

More charts

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Aclaris Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.2 USD

Average target price

1.8 USD

Spread / Average Target

+50.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACLARIS THERAPEUTICS, INC.	+14.29%	85.52M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research